Braasch Biotech Receives Second Patent for Farm Animal Productivity Vaccines
Braasch Biotech's alternative vaccine for farm animal productivity awarded second US patent
(Garretson, South Dakota) Braasch Biotech LLC was assigned US Patent 7,943,143B2 on May 17, 2011. The patent further expands Braasch's anti-hormone vaccine technologies for farm animal productivity. The patent, Chloramphenicol Acetyl Transferase (CAT)-Defective Somatostatin Fusion Protein And Uses Thereof, is the second US Patent Braasch has received within the last year.
"Our impressive vaccine technologies provide a safe and cost-effective benefit to American Animal Agriculture and also for securing the global protein-food supply chain. ", stated Dr. Keith Haffer, President and Chief Scientific Officer of Braasch. "In one capacity, our vaccines will be used as an alternative method to benefit the swine industry nationally and globally, rather than use antibiotics to enhance animal growth."
A May 13, 2011 article in the Wall Street Journal, referencing Rep. Louise Slaughter (D., N.Y.), reported that livestock raised in the US are administered more than 20 million tons of antibiotic in their feed, raising concerns that mass dosing increases risks to human health. Dr Haffer further elaborated on this article, " By vaccinating pigs with the Braasch vaccine, we utilize the animal's own immune system to increase lean muscle mass and circumvent the need to feed antibiotics, thus reducing possible emergence of antibiotic resistance in bacteria that can threaten human health."
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.
About Braasch Biotech
Braasch is a privately held biopharmaceutical company located in South Dakota. The company has additional affiliations in California, Iowa, Colorado and New Jersey.
Contact Information
Jeralyn Kay Braasch
CEO
Tel. 605-376-8752
Fax. 605-594-6256
PR Courtesy of Online PR News: http://bit.ly/lUDhRH
(Garretson, South Dakota) Braasch Biotech LLC was assigned US Patent 7,943,143B2 on May 17, 2011. The patent further expands Braasch's anti-hormone vaccine technologies for farm animal productivity. The patent, Chloramphenicol Acetyl Transferase (CAT)-Defective Somatostatin Fusion Protein And Uses Thereof, is the second US Patent Braasch has received within the last year.
"Our impressive vaccine technologies provide a safe and cost-effective benefit to American Animal Agriculture and also for securing the global protein-food supply chain. ", stated Dr. Keith Haffer, President and Chief Scientific Officer of Braasch. "In one capacity, our vaccines will be used as an alternative method to benefit the swine industry nationally and globally, rather than use antibiotics to enhance animal growth."
A May 13, 2011 article in the Wall Street Journal, referencing Rep. Louise Slaughter (D., N.Y.), reported that livestock raised in the US are administered more than 20 million tons of antibiotic in their feed, raising concerns that mass dosing increases risks to human health. Dr Haffer further elaborated on this article, " By vaccinating pigs with the Braasch vaccine, we utilize the animal's own immune system to increase lean muscle mass and circumvent the need to feed antibiotics, thus reducing possible emergence of antibiotic resistance in bacteria that can threaten human health."
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.
About Braasch Biotech
Braasch is a privately held biopharmaceutical company located in South Dakota. The company has additional affiliations in California, Iowa, Colorado and New Jersey.
Contact Information
Jeralyn Kay Braasch
CEO
Tel. 605-376-8752
Fax. 605-594-6256
PR Courtesy of Online PR News: http://bit.ly/lUDhRH
Follow us
What people say
“We have generated many, many press clippings and improved our SEO ranking from the services that EIN Presswire provides us. Easy and simple way to upload and distribute our press releases. I would recommend their services.”
— Chris Morris, Marketing Manager of Mountz Inc.
“I have been using the EIN Press Release service for more than three years in entertainment & health care industries. Their account managers and the placement of my press releases online has been above reproach reaching mainstream journalists to help further client and brand visibility. I highly recommend this service for global notoriety and am thankful I made that first call.“
— Monica Anders PR Strategist 25 Years!
Our Partners
Press releases
- Atlanta Airport Hotel Lets Guests Save 15% or More with The Great Getaway Offer [23 May 2012] 24-7 pressrelease
- AsiaRooms.com - Asia International Guitar Festival and Competition Returns to Bangkok [23 May 2012] 24-7 pressrelease
- Manufacturing in Mexico Events to be Hosted this Fall by The Offshore Group [23 May 2012] 24-7 pressrelease
- AsiaRooms.com - Celebrate Pineapple Nang Lae and Lin Chee Chiang Rai Festival in Thailand [23 May 2012] 24-7 pressrelease
- Cleanfinancial.com Creates New Guide to Speculating on Facebook Shares [23 May 2012] 24-7 pressrelease
© 2005-2012